BUSINESS
Fed: There are things like the Virus which money can’t buy, for everything else it’s the US FED
This however doesn’t take away the risks. The virus is the central risk. It can jeopardise and delay the economic recovery, leading to more financial instability
BUSINESS
Nestle: Strong cash flows help it combat headwinds
Investors should take comfort from the fact that Nestle has continued to focus on innovation and has launched 71 new products since 2016
BUSINESS
Tech Mahindra – Better numbers may support a trading rally
The geo-political tug of war is a crucial factor for the 5G rollout and hence, Tech Mahindra sees this opportunity coming in phases. We see the play panning out from H2 FY22 onwards
BUSINESS
Pharma: Trump’s executive orders may possibly provide better market access opportunities
Indian drugmakers such as Cipla, Cadila, Lupin, Dr Reddy’s, Sun Pharma and a few small-sized pharma companies such as Laurus Labs may benefit from a likely revamp of US medicare
BUSINESS
Himadri Speciality: Outcome of carbon black anti-dumping review a key event to watch
Himadri Speciality's valuations are still ahead of peers in the carbon space but justified due to diversified and vertically integrated portfolio
BUSINESS
Balaji Amines — Time to book profit
Balaji Amines' operating margins take on shine on the back of softening raw material prices and a better product mix
ANNOUNCEMENTS
RIL AGM | Google on board; 5G ready
The RIL AGM saw two big-bang announcements: Google’s investment in Jio Platforms, which was more or less expected, and being 5G ready with solutions
BUSINESS
How to position your portfolio for the coming US elections
A potential change of US regime in favour of the Democrats can have a salubrious impact on the “equity risk premium” - as a more collaborative world would reduce risk.
BUSINESS
Rossari Biotech: Healthy long-term prospects, but richly valued IPO
Rossari is led by technocrats having strong domain knowledge, which in turn has helped in superior execution of capex projects in the past and diversification to new end markets
BUSINESS
Navin Fluorine: Time to book gains?
In medium term, Navin Fluorine's growth should be driven by higher margin businesses of CRAMS and specialty business segments
BUSINESS
Bodal Chemicals could benefit from the attempt to curb Chinese imports
The Bodal Chemicals stock should command a valuation premium because of its vertically integrated business model
BUSINESS
IPCA Labs guidance should move investor focus beyond HCQS, accumulate
There is much more to IPCA Labs than the HCQS opportunity. Its FY21 guidance reflects that.
BUSINESS
Galaxy Surfactants: Growing demand for personal hygiene products a game changer?
Stiffer intensity, uncertain demand environment and lower discretionary spending pose key risks
BUSINESS
Aarti Industries: The risk of contract termination becoming a trend for the industry
This rethink is being fuelled by the uncertain demand situation at present, which is reflecting in the desire to lower supply chain risk, change outsourcing contracts and calibrate capex growth.
BUSINESS
What does the Fed’s stance imply for stock markets brimming with liquidity?
Fed’s dot plot clearly conveys a strong consensus for “lower for longer” rates. On top of that, the Fed ascertains that policy tools/stimulus measures would be used “forcefully, proactively and aggressively” as the need arise to support economy.
BUSINESS
Apcotex Industries: Adverse demand-supply balance poses a risk
BUSINESS
SRF: Building a specialty chemicals business block by block
BUSINESS
Aurobindo: Traction in complex generics is vital to its health
BUSINESS
Britannia: Advantage Supply Chain
BUSINESS
Lupin: A watershed year for the US business?
BUSINESS
The wait for Sun Pharma to rise gets longer
BUSINESS
Dabur Q4: Is elevated rural exposure Dabur’s Achilles heel?
BUSINESS
Aarti Industries Q4: Near-term uncertainty leads to capex deferral
BUSINESS
Dr Reddy’s: Primed by strong bets on complex pharma opportunities, good for risk takers
